Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Avior Wealth Management LLC

Avior Wealth Management LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 5.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,799 shares of the company’s stock after buying an additional 343 shares during the quarter. Avior Wealth Management LLC’s holdings in Vaxcyte were worth $257,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of PCVX. Wells Fargo & Company MN raised its stake in Vaxcyte by 53.7% during the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company’s stock worth $5,916,000 after acquiring an additional 25,257 shares in the last quarter. Rhumbline Advisers raised its stake in Vaxcyte by 5.5% during the 1st quarter. Rhumbline Advisers now owns 181,230 shares of the company’s stock worth $6,843,000 after acquiring an additional 9,416 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after acquiring an additional 260 shares in the last quarter. Parallel Advisors LLC raised its stake in Vaxcyte by 203.6% during the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock worth $61,000 after acquiring an additional 1,071 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its stake in Vaxcyte by 30.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,017,845 shares of the company’s stock valued at $83,321,000 after purchasing an additional 236,940 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Stock Performance

Shares of PCVX opened at $32.87 on Monday. The company has a market capitalization of $4.24 billion, a price-to-earnings ratio of -8.24 and a beta of 1.20. The company’s 50 day simple moving average is $33.00 and its 200 day simple moving average is $60.78. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the previous year, the business earned ($0.85) EPS. Equities analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of recent research reports. Bank of America dropped their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. The Goldman Sachs Group dropped their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They set an “overweight” rating on the stock. Finally, Guggenheim reissued a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and a consensus price target of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.